

LITERATURA

1. Koudelková, M et al. ProstateScreening.cz – Program časného záchytu karcinomu prostaty [online]. Praha: Ústav zdravotnických informací a statistiky ČR, 2024. [cit. 2025-08-22]. Available from: <https://www.prostateScreening.cz>. Verze 1.0
2. Ikushima S, Ono R, Fukuda K, et al. Trousseau's syndrome: cancer-associated thrombosis. *Jpn J Clin Oncol*. 2016;46(3):204-208.
3. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. *Nat Rev Dis Primers*. 2022;8(1):11.
4. Leblanc K, Edwards SJ, Dranitsaris G, et al. Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus. *Cancers (Basel)*. 2024;16(19):3336.
5. Dai C, Dehm SM, Sharifi N. Targeting the Androgen Signaling Axis in Prostate Cancer. *J Clin Oncol*. 2023;41(26):4267-4278.
6. Gregorová J, Tašková I. Antikoagulační terapie. Praha: Maxdorf; 2022.
7. American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024.
8. Chen Y, Zhou Q, Hankey W, et al. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. *Cell Death Dis*. 2022;13(7):632.
9. Soumarová R. Onkologie. Praha: Univerzita Karlova, nakladatelství Karolinum; 2025.
10. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science*. 2009;324(5928):787-790.
11. Souhrn údajů o přípravku (SPC) – Xtandi; 2025
12. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. *Cancer Res*. 2012;72(6):1494-503.
13. de Vries R, Jacobs F, Mannens G, et al. Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes. *Drug Metab Dispos*. 2019;47(5):453-464.
14. Duran I, Carles J, Bulat I, et al. Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer. *Clin Pharmacokinet*. 2020;59(9):1135-1148.
15. Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. *Sci Rep*. 2015;5:12007.
16. Zurth C, Koskinen M, Fricke R, et al. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. *Eur J Drug Metab Pharmacokinet*. 2019;44(6):747-759.
17. Shore N, Zurth Ch, Fricke R, et al. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. *Target Oncol*. 2019;14(5):527-539.
18. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. *J Clin Oncol*. 2010;28(9):1496-501.
19. Han CS, Patel R, Kim IY. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. *Expert Opin Drug Metab Toxicol*. 2015;11(6):967-975.
20. Montgomery RB, Vessella R, Mostaghel E, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. *Cancer Res*. 2008;68(11):4447-4454.
21. Ando T, Nishiyama T, Takizawa I, et al. Dihydrotestosterone synthesis pathways from inactive androgen 5 α -androstane-3 β ,17 β -diol in prostate cancer cells: Inhibition of intratumoral 3 β -hydroxysteroid dehydrogenase activities by abiraterone. *Sci Rep*. 2016;6:32198.
22. Li R, Evalou K, Sharma KK, et al. Abiraterone inhibits 3 β -hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. *Clin Cancer Res*. 2012;18(13):3571-3579.
23. Acharya M, Bernard A, Gonzalez M, et al. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. *Cancer Chemother Pharmacol*. 2012;69(6):1583-1590.
24. Souhrn údajů o přípravku (SPC) – Zytiga; 2025.
25. Büchler T. Klinická onkologie. Praha: Maxdorf; 2023.
26. Ferri N, Colombo E, Tenconi M, et al. Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. *Pharmaceutics*. 2022;14(6):1120.
27. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2022;43(7):561-632.
28. Arachchilage DJ, Platten S, Hickey K, et al. Guidelines on the investigation and management of antiphospholipid syndrome. *Br J Haematol*. 2024;205(3):855-880.
29. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med*. 2003;349(2):146-153.
30. Meyer G. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. *Arch Intern Med*. 2002;162(15):1729-1735.
31. Lee YJ, Park J-K, Uhm J-S, et al. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. *Int J Cardiol*. 2016;203:372-378.
32. Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. *Thromb Haemost*. 2020;120(7):1128-1136.
33. Sabatino J, De Rosa S, Polimeni A, et al. Direct Oral Anticoagulants in Patients With Active Cancer: A Systematic Review and Meta-Analysis. *JACC CardioOncol*. 2020;2(3):428-440.
34. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. *N Engl J Med*. 2018;378(7):615-624.
35. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. *N Engl J Med*. 2020;382(17):1599-1607.
36. Górnicki T, Buldys K, Zielińska D, et al. Direct-Acting Oral Anticoagulant Therapy in Cancer Patients-A Review. *Cancers (Basel)*. 2023;15(10):2697.
37. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. *Blood*. 2019;133(4):291-298.
38. Hindley B, Lip GYH, McCloskey AP, et al. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. *Expert Opin Drug Metab Toxicol*. 2023;19(12):911-923.
39. Souhrn údajů o přípravku (SPC) – Pradaxa; 2025
40. Byon W, Garonzik S, Boyd RA, et al. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. *Clin Pharmacokinet*. 2019;58(10):1265-1279.
41. Souhrn údajů o přípravku (SPC) – Eliquis; 2025.
42. Kvasnička T, Malikova I, Zenahlikova Z, et al. Rivaroxaban – Metabolism, Pharmacologic Properties and Drug Interactions. *Curr Drug Metab*. 2017;18(7):636-642.
43. Souhrn údajů o přípravku (SPC) – Xarelto; 2025.
44. Souhrn údajů o přípravku (SPC) – Lixiana; 2025.
45. Mar PL, Gopinathannair R, Gengler BE, et al. Drug Interactions Affecting Oral Anticoagulant Use. *Circ Arrhythm Electrophysiol*. 2022;15(6):e007956.
46. Souhrn údajů o přípravku (SPC) – Warfarin Orion; 2025.
47. Shatzel JJ, Daughety MM, Olson SR, et al. Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. *J Oncol Pract*. 2017;13(11):720-727.
48. Otsuka Y, Poondru S, Bonate PL, et al. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. *J Pharmacokinet Pharmacodyn*. 2023;50(5):365-376.
49. Lennep BW, Mack J, Poondru S, et al. Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy. *Drug Saf*. 2024;47(7):617-641.
50. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. *Europace*. 2021;23(10):1612-1676.
51. Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic Drug Interaction Studies with Enzalutamide. *Clin Pharmacokinet*. 2015;54(10):1057-1069.
52. Parrett JL, Reaves AB, Self TH, et al. Enzalutamide-warfarin interaction necessitating warfarin dosage adjustment: A case report of successful clinical management. *J Clin Pharm Ther*. 2018;43(2):276-279.
53. Casserly EA, Rogers SE, Keisner SV. Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient. *J Oncol Pharm Pract*. 2017;23(1):68-70.
54. Potdar R, Gartrell BA, Given R, et al. Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies. *Am J Cancer Res*. 2022;12(1):445-450.
55. Souhrn údajů o přípravku (SPC) – Erleada; 2025.
56. Podgoršek E, Mehra N, van Oort IM, et al. Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide. *Clin Pharmacokinet*. 2023;62(8):1049-1061.
57. Boujonnier F, Lemaitre F, Scailteux LM. Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information. *Cardiovasc Drugs Ther*. 2024;38(4):757-767.
58. Souhrn údajů o přípravku (SPC) – Nubeqa; 2025.
59. Benoist GE, Hendriks RJ, Mulders PFA, et al. Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. *Clin Pharmacokinet*. 2016;55(11):1369-1380.
60. Monbaliu J, Gonzalez M, Bernard A, et al. In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. *Drug Metab Dispos*. 2016;44(10):1682-1691.
61. Dubinsky S, Thawer A, McLeod AG, et al. Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone. *Support Care Cancer*. 2019;27(9):3209-3217.
62. Mithoowani S, Tan CW, Siegal DM. Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions. *Int J Lab Hematol*. 2025 Apr 22.